Solid-phase peptide synthesis that operates with Fmoc chemistry introduces D-tyrosine predominantly as Fmoc-D-Tyr(tBu)-OH or Boc-D-Tyr(tBu)-OH rather than as the unprotected amino acid. The tert-butyl ether on the phenolic oxygen remains stable through repetitive piperidine-mediated Fmoc removal—typically 20% v/v piperidine in dimethylformamide at 25°C for 2 × 5 min—but is cleaved during final acidolysis with trifluoroacetic acid. On Wang resin or 2-chlorotrityl chloride resin with substitution densities of 0.4–0.6 mmol/g, the first coupling is commonly conducted with 2–4 equiv of protected D-tyrosine relative to resin amino groups, activated by HBTU/DIPEA or HATU/2,4,6-collidine in DMF at 25–30°C for 30–60 min. Coupling completeness is verified by Kaiser or TNBS test; when free amines persist, a recoupling with 1.5–2.0 equiv is executed before the next elongation. Process challenges observed on synthesis lines include partial tert-butyl loss under prolonged TFA exposure—especially when cleavage is extended beyond 3 h—and racemization risk under excess base or high-temperature coupling. Chiral purity of the isolated peptide is therefore monitored after total hydrolysis by HPLC with a chiral stationary phase and by ion-pair chromatography.

Compliance for peptide APIs derived from this starting material is governed by ICH Q7 for good manufacturing practice, ICH Q11 for development and manufacture of drug substances, ICH Q6A for specification setting, and ICH Q3D for elemental impurities. Residual solvent limits follow ICH Q3C, with dimethylformamide in the final peptide controlled below 880 ppm under the class 2 limit. The D-tyrosine derivative must be released with a certificate including identity by infrared and specific rotation, enantiomeric excess by chiral HPLC, related substances by reverse-phase HPLC, and residue on ignition. Downstream process units after solid-phase synthesis include preparative reversed-phase HPLC on C18 silica columns with acetonitrile/water gradients modified by 0.1% TFA or 0.1% acetic acid, ion exchange to convert the peptide to acetate or hydrochloride salt, nanofiltration, and lyophilization. Terminal product types include injectable peptide APIs, depot formulations, diagnostic peptide probes, and peptide-drug conjugates in which the D-tyrosine residue is introduced to extend circulating half-life or reduce immunogenicity.

How Is Enantiomeric Contamination Quantified When L-Tyrosine Batches Are Released?

In chiral release testing for L-tyrosine and its derivatives, the D-enantiomer is specified as an impurity marker. Quantification uses HPLC with chiral stationary phases based on cellulose or amylose derivatives, or ligand-exchange columns with copper(II)-amino acid complexes. Calibration solutions of D-tyrosine are prepared at 0.1–1.0 mg/mL in 0.1 M HCl or mobile phase; linearity is generally established from 0.05% to 2.0% relative to the L-tyrosine main peak. Detection at 225 nm or 274 nm is used because the phenolic chromophore gives adequate molar absorptivity without derivatization. For the certified reference material itself, the production route includes recrystallization from water/ethanol mixtures, vacuum drying at 40°C to constant weight, homogenization, and bottling under argon. Certification relies on mass balance, quantitative NMR, and HPLC-UV/ELSD with purity assigned under ISO 17034 for reference material producers. Testing laboratories operate under ISO/IEC 17025, and pharmacopeial optical rotation measurements follow USP 781 with a sodium lamp at 589 nm; specific rotation for D-tyrosine is typically reported as +10.0° to +11.0° at 25°C in 1 M HCl. Finished product types are analytical reference standards, chiral method development kits, system suitability mixtures, and spiked matrix controls used in peptide raw material release.

Oxidative Stability Limits in D-Tyrosine–Modified Topical Peptides

Because cutaneous aminopeptidases and carboxypeptidases rapidly degrade L-configuration peptide actives, topical peptide active ingredients that contain D-tyrosine are designed to resist enzymatic hydrolysis in the stratum corneum and upper dermis. The cosmetic safety assessment follows Regulation (EC) No 1223/2009, with the peptide active evaluated for phototoxicity, ocular irritation, and dermal sensitization; the D-tyrosine-derived peptide must be listed by INCI name and supported by a cosmetic product safety report under Annex I. In formulation, the finished peptide active concentration is typically in the range of 0.001–0.05 wt% in serums, creams, and masks, while D-tyrosine as an intermediate is consumed stoichiometrically during solid-phase synthesis and is not intentionally present as unreacted monomer. Production processes include Fmoc-based peptide assembly, preparative high-pressure liquid chromatography purification to cosmetic peptide purity above 95%, solvent exchange to ethanol or glycerin, and incorporation into oil-in-water emulsions using high-shear mixers at 3,000–8,000 rpm. Terminal product types include anti-aging serums, eye contour creams, and peptide-infused sheet masks where the peptide active is claimed for skin firmness or elasticity; stability is assessed by ISO 11930 challenge testing and real-time storage at 25°C/60% RH for 24 months.

Across polyamide reverse-osmosis membranes and open recirculating cooling circuits, biofouling proceeds when extracellular polymeric substances anchor sessile populations to the surface; D-amino acids have been investigated as non-biocidal agents that interfere with peptide crosslinks in the biofilm matrix. D-tyrosine has been evaluated in laboratory flow cells and pilot-scale membrane fouling simulators because its phenolic side chain may reduce hydrophobic interactions between matrix proteins and membrane surfaces. Dosing is typically prepared as a saturated aqueous stock solution at 0.4–0.5 g/L at 25°C, because higher neutral-pH concentrations are limited by amino acid solubility; this stock is metered through a side-stream mixing skid with a low-shear centrifugal dosing pump to avoid precipitation of divalent cations in hard water. Published data for field-scale biofilm control is limited, and no universal target contact concentration can be stated without site-specific biofilm characterization; laboratory flow-cell studies report strain-dependent effects in the low micromolar to submillimolar range, while feedwater alkalinity above 200 mg/L as CaCO₃ may reduce availability by complexation. Because D-tyrosine is not an approved antimicrobial, any use in the United States must be assessed under FIFRA and in the European Union under Regulation (EU) No 528/2012 if a biocidal claim is made; if used as a process aid or antifouling adjunct without a biocidal claim, the legal status is different and must be confirmed by the formulator. No industrial-scale biofilm efficacy standard has been harmonized, though laboratory screening often uses ASTM E2871-21 or ASTM E2647-20 methods adapted to membrane coupons. Terminal product types are pilot-scale membrane maintenance additives, cooling water antifouling programs, and research-use biofilm dispersal kits.

When D-Tyrosine Serves as a Stereochemical Probe in Oxidase Assays

When D-amino acid oxidase-catalyzed oxidation is screened for substrate selectivity, D-tyrosine is operated as a stereochemical probe because the phenolic side chain lowers catalytic efficiency relative to D-alanine or D-phenylalanine but provides a distinctive UV signature for monitoring. Assay conditions reported in screening laboratories include 10–50 mM D-tyrosine in 50 mM phosphate buffer at pH 8.0 and 25°C, with hydrogen peroxide detected by horseradish peroxidase-coupled chromogenic reagents at 570 nm. The process is run in microtiter plates or jacketed stirred reactors with dissolved oxygen maintained above 30% saturation; enzyme immobilization on epoxy-activated methacrylate beads is assessed by specific activity retention after multiple cycles. Compliance for this type of industrial biocatalysis work follows ISO 9001 for quality management and REACH for handling of the amino acid; if the D-tyrosine is used in pharmaceutical enzyme manufacturing, ICH Q7 may apply to the enzyme as a processing aid. D-tyrosine addition is not a formulation ratio but an assay substrate concentration; however, preparative oxidations have used 50–100 mM substrate loads in stirred-tank reactors. Finished product types from this application are immobilized DAAO biocatalysts, enzyme screening kits, and the corresponding α-keto acid, 4-hydroxyphenylpyruvate, as a research chemical.

Chiral Organocatalyst Feedstocks from Phenolic D-Amino Acid Scaffolds

Chemical transformation of D-tyrosine into chiral ligands and organocatalysts is performed through a sequence that preserves the C₂ configuration while converting the carboxylic acid and amine into coordinating groups. The phenolic oxygen is first protected as the tert-butyl ether or benzyl ether, then the α-amino acid is reduced to the corresponding amino alcohol with borane or lithium aluminum hydride, and the amino alcohol is condensed with carboxylic acids or heterocyclic esters to form oxazoline, bisoxazoline, or salen-type donors. Process development laboratories use tetrahydrofuran or dichloromethane as solvent, with reaction temperatures controlled between −20°C and 25°C during hydride reduction and enantiomeric excess verified by chiral HPLC after derivatization. Compliance for catalyst feedstocks is less standardized than for pharmaceutical or cosmetic use; material registration under REACH applies in the European Union, and workplace handling follows ISO 45001 or local occupational exposure limits. Addition ratios for downstream catalytic reactions are catalyst loadings, typically 0.5–5 mol% relative to substrate in asymmetric transformations; ligand-to-metal ratios of 1:1 to 2:1 are used with copper, palladium, or ruthenium salts. Finished product types include chiral oxazoline ligands, bisoxazoline ligands, and imine-based organocatalysts sold as research chemicals or custom synthesis intermediates for agrochemical and pharmaceutical process development.